Venture Certified
| 연구개발유형 | 2023-04-27 ~ 2026-04-26 | 20230427020003 | 2023-04-27 |
| Item | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 0.0B | 0.0B | 0.0B |
| Operating Profit | -7.7B | -2.6B | -1.9B |
| Net Profit | -6.1B | -2.6B | -1.9B |
| Total Assets | 9.3B | 4.8B | 6.1B |
| Total Liabilities | 11.6B | 1.6B | 0.3B |
| Total Equity | -2.3B | 3.2B | 5.8B |
Capital Erosion: Total equity is negative or below 50% of capital stock
Operating Loss: Op. profit -8B
3 Consecutive Years of Net Loss
- 0.0%
▼ 244.3%
▼ 1953.4%
▲ 567.7%
| Name | Position | Role |
|---|---|---|
| 신현진 | 대표이사 | 대표 |
No Data – Contact
No procurement record or data not yet available| Tax Type | 부가가치세 일반과세자 |
| Status | Cert. flags confirmed (details update after further collection) |
1 Additional Data Sources
{
"address": "대전광역시 유성구",
"ceo_name": "신현진",
"certificate": [
{
"cert_number": "20230427020003",
"changes": "",
"disclosure_date": "2023-04-27",
"first_cert_date": "2023-04-27",
"no": "1",
"type": "연구개발유형",
"valid_period": "2023-04-27 ~ 2026-04-26"
}
],
"company_name": "(주)셀엔백스",
"corp_no": "160111-*******",
"financials": {
"2022": {
"capital_stock": 388275000,
"cost_of_sales": 0,
"current_assets": 348284000,
"current_liabilities": 28583000,
"gross_profit": 0,
"net_income": -189023000,
"net_income_bs": -189248000,
"non_current_assets": 263368000,
"non_current_liabilities": 0,
"non_operating_expenses": 3330000,
"non_operating_income": 977000,
"operating_profit": -186670000,
"revenue": 0,
"sga_expenses": 186670000,
"total_assets": 611652000,
"total_equity": 583069000,
"total_liabilities": 28583000
},
"2023": {
"capital_stock": 388275000,
"cost_of_sales": 0,
"current_assets": 202788000,
"current_liabilities": 8882000,
"gross_profit": 0,
"net_income": -261418000,
"net_income_bs": -261418000,
"non_current_assets": 277745000,
"non_current_liabilities": 150000000,
"non_operating_expenses": 1224000,
"non_operating_income": 233000,
"operating_profit": -260427000,
"revenue": 0,
"sga_expenses": 260427000,
"total_assets": 480533000,
"total_equity": 321651000,
"total_liabilities": 158882000
},
"2024": {
"capital_stock": 439275000,
"cost_of_sales": 0,
"current_assets": 650035000,
"current_liabilities": 6007000,
"gross_profit": 0,
"net_income": -610803000,
"net_income_bs": -610803000,
"non_current_assets": 276234000,
"non_current_liabilities": 1150000000,
"non_operating_expenses": 13899000,
"non_operating_income": 172813000,
"operating_profit": -769717000,
"revenue": 0,
"sga_expenses": 769717000,
"total_assets": 926269000,
"total_equity": -229738000,
"total_liabilities": 1156007000
}
},
"industry": "의학 및 약학 연구개발업",
"investment": [],
"main_products": "백신, 진단키트, 치료제 외",
"phone": "042-821-****",
"years": [
2024,
2023,
2022
]
}